Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRK2 | P25098 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588770 | 0.82 | FDPS (0.44) | FDPSRAB9AMDM2ROCK2ROCK1 | |
| SCHEMBL8351920 | 0.81 | GAA (0.48) | RAB9AGAALMNAALDH1A1KDM4E | |
| SCHEMBL13588767 | 0.80 | RAB9A (0.48) | RAB9ALMNAALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL9911482 | 0.79 | GAA (0.46) | FDPSRAB9AMDM2GAAROCK2 | |
| SCHEMBL13589463 | 0.79 | MDM2 (0.48) | FDPSRAB9AMDM2GAAROCK2 | |
| SCHEMBL11481061 | 0.78 | MDM2 (0.52) | FDPSRAB9AMDM2GAAROCK2 | |
| SCHEMBL12380252 | 0.78 | MEN1 (0.46) | GAALMNAALDH1A1GRK2SMN1; SMN2 | |
| SCHEMBL6765899 | 0.76 | BCHE (0.54) | RAB9AMDM2ROCK2ROCK1BCHE | |
| SCHEMBL7723775 | 0.76 | BCHE (0.53) | FDPSMDM2GAAROCK2BCHE | |
| SCHEMBL20389264 | 0.76 | GAA (0.49) | FDPSRAB9AMDM2GAAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | FDPS 2739/4885RAB9A 4109/4885MDM2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.